In Vitro Validation Study of HER2 and HER4 Mutations Identified in an Ad hoc Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
The LUX-Lung 8 randomized trial (LL8) demonstrated a prolonged progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) of the lung after treatment with afatinib compared with erlotinib. A secondary analysis of the LL8 reported that the presence of rare HER2/HER4 mutations may be partly responsible for this result. Patients with HER2 (hazard ratio [HR] 0.06/p-value 0.02) or HER4 (HR 0.21/p-value unreported) mutations had longer PFS after treatment with afatinib. However, the biological function of these mutations is unclear.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | HER2 | Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Tarceva